Although rare overall, choroidal melanoma is the most common intraocular cancer in adults, with an incidence of approximately 11,000 patients per year in the United States and Europe. The standard of care remains radiotherapy, which frequently results in irreversible vision loss. There are no FDA-approved therapies for choroidal melanoma.
The company we are profiling today is Aura Biosciences Inc. (AURA), whose lead drug candidate is in a global phase 3 trial for the first-line treatment of early-stage choroidal melanoma.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.